Podcasts about Cart

Many see Amazon as a reliable source of consumer goods from toilet paper to wireless headphones. But Sean McLain reports that the “everything store” is now betting that consumers will also pick up much bigger items when given the opportunity. Plus, Imani Moise reports on why fintech company Block is sharing its version of a credit store with customers. Patrick Coffee hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A MoDot engineer joins Chris and Amy to explain what happened to snow removal yesterday; Amy wants to ride the giant Schnucks shopping cart; Sean Malone shares the story of one truck driver shooting another on I-55; Blues netminder Jordan Binnington was angry after being pulled last nite.

God is asking you to follow him in a way that will require your faith. You're not going to understand it. You're not going to be in control of it. Can your mind make peace with the unknown? Can your hands remain open in full surrender? And girl, will your feet move forward to destination […]

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

In today's Tech3 from Moneycontrol, we break down Myntra's next wave of global expansion, LTIMindtree's decision to halt new H-1B filings, and Skyroot's warning on the global small-rocket shortage. We also discuss the government's directive to preinstall the Sanchar Saathi cybersecurity app on all smartphones and why influencers are still struggling to adapt to new AI-labelling rules

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Os passageiros do Metrô agora podem pagar a tarifa diretamente em catracas exclusivas das estações, utilizando cartões físicos de débito e crédito com tecnologia de aproximação. A iniciativa faz parte de um novo projeto piloto, iniciado nesta segunda-feira (1), com duração inicial de seis meses e possibilidade de prorrogação, que busca avaliar a aceitação dos passageiros e ajustes que possam ser feitos.

Hablamos de traumatología con los mejores especialistas de la Clínica CEMTRO, referente absoluto en cirugía traumatológica deportiva además centro médico de excelencia FIFA. La Dra. Isabel Guillén es traumatóloga experta en cirugía de pie, tobillo y patologías del cartílago articular. Jefa de la Unidad de Cartílago en Clínica CEMTRO, forma también parte del equipo de la Unidad de Rodilla, Unidad de Pie y Tobillo, y también de CEMTRO Premium. Su trayectoria está centrada en el tratamiento de condropatías, osteocondritis disecante y artrosis. See omnystudio.com/listener for privacy information.

O áudio-árbitro Pedro Henriques considera que ficou por mostrar um cartão amarelo a Boma, William Gomes e ainda Ferro. Nota 6. "Árbitro acertou no essencial. Gestão disciplinar foi regular".See omnystudio.com/listener for privacy information.

00:00 O contrato de pobreza que você assinou01:08 Item 01 - O erro clássico que cria a bola de neve02:45 Item 02 - Queimando dinheiro (literalmente)04:02 Item 03 - A morte por mil cortes05:34 Item 04 - O trapo de ouro (Cuidado com isso!)06:59 RC Club09:17 Item 05 - O recado para os marombas11:14 Item 06 - Noite de rei, vida de plebeu12:38 Item 07 - A ilusão de ótica que dói no ego 14:39 RC Wealth

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

Reprise des négos avec les médecins. Crise au PLQ: l’UPAC se mêle du dossier. Le PM Carney se rend à Calgary et Washington. Suivi de la fusillade à Washington. Une série québécoise gagne un Emmy International. Solide prestation du CH! Une grosse acquisition au monticule pour les Jays. Tout savoir en quelques minutes avec Audrey Gagnon, Isabelle Perron et Mario Dumont. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Descubra tudo sobre o Cartão Azul Itaú Mastercard Skyline: benefícios exclusivos, vantagens para acumular pontos, acesso a salas VIP, descontos em passagens aéreas e muito mais. Neste podcast, exploramos como o cartão pode transformar sua experiência de viagem, aumentar sua praticidade no dia a dia e oferecer recompensas que fazem a diferença. Se você busca informações claras e dicas práticas para aproveitar ao máximo seu cartão de crédito, este é o lugar certo.Solicite o seu cartão de crédito https://tinyurl.com/3nkc6e7cCÓDIGOS DE INDICAÇÃO CARTÃO DE CRÉDITOhttps://bit.ly/3RuEZ21GRUPO GRATUITO NO WHATSAPPhttps://tinyurl.com/5n79dtkmLivros sobre Educação Financeira https://amzn.to/47uuEY2Nosso site https://girofinanceiro.com.br/Canal do Youtube https://tinyurl.com/43jux7mr

Santa, baby! We're here to deliver the #damngood gifts of the season that the beauty lover on your list will *actually* want - no snoozefest presents in sight. Watch, and subscribe to this episode on YouTube! You'll hear about:The makeup musts we're swooning over (a luxury blush trio, lip gloss “stacks,” and a palette fit for Celine Dion)A makeup-meets-indie jewellery collab that's sure to spark conversation at any holiday party A chic AF bar soap gift set that's giving us major flashbacks to a coveted childhood stocking stufferThe high quality hair clips that not only hold up the thickest hair, but that are also the hottest style accessory of the season A French-girl approved advent calendar that doesn't skimp out on beauty goodiesA limited edition version of a 100-year old fragrance that's been updated for the vanilla lover on your list! (And the insider tip for how you can personalize it.) One of the most-searched for beauty gifts of the season, revealed (this one might surprise you!) Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this: Shop Smarter, Not Harder – How-to Get Real Value from Your Beauty Buys

Send us a textWe explore how clear data, simple habits, and dietitian guidance can cut through grocery aisle confusion and help people make faster, healthier choices. Galen from GreenChoice shares new findings on ultra-processed foods, why retailers matter, and how personalization empowers every shopper.• founding spark in the egg aisle and the problem with label claims• upbringing, athletics and the path to building transparent food data• how the GreenChoice score and app work across four health pillars• support for allergies, celiac disease and diabetes through filters• sobering stats on highly processed foods by category and retailer• shopper trends toward fewer additives and more ingredient clarity• a three-step label reading method that saves time• the role of dietitians, personalization and shelf-level tools• AI, wearables and the future of real-time nutrition guidance• community and family dynamics that make change stick• practical staples and what's next for GreenChoiceGo check it out. It's an incredible resource for anyone who wants to eat well and shop with confidence. Thank you for listening. Please subscribe to this podcast and share with a friend. If you would like to know more about my services, please message at fueledbyleo@gmail.comMy YouTube Channel https://www.youtube.com/channel/UC0SqBP44jMNYSzlcJjOKJdg

Para Pedro Henriques, o VAR foi "crucial" para corrigir o cartão vermelho inicialmente mostrado ao jogador do Sporting. Dá nota 7, uma arbitragem positiva, com destaque para a importância do VAR.See omnystudio.com/listener for privacy information.

Invités :Général Emmanuel de Richoufftz, vice-président de Place d'armes.Gauthier Le Bret, journaliste.Eric Naulleau, journaliste.Louis de Raguenel, chef du service politique d'Europe 1.Sabrina Medjebeur, essayiste-sociologue.Eric Revel, éditorialiste politique.Marc Fiorentino, économiste. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

This month, the gals bless us with their long-time bestie, the famous Blortney! Topics include guinea pig parties, overturned monkeys, a poopy pants puzzle, and eyebrow innovation. Don't be a stinker and a meanie, tune in for November's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartnerSee omnystudio.com/listener for privacy information.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Episodio exclusivo para suscriptores de Se Habla Español en Apple Podcasts, Spotify, iVoox y Patreon: Spotify: https://open.spotify.com/show/2E2vhVqLNtiO2TyOjfK987 Patreon: https://www.patreon.com/sehablaespanol Buy me a coffee: https://www.buymeacoffee.com/sehablaespanol/w/6450 Donaciones: https://paypal.me/sehablaespanol Contacto: sehablaespanolpodcast@gmail.com Facebook: www.facebook.com/sehablaespanolpodcast Twitter: @espanolpodcast Hola, ¿cómo va todo? Aquí en Luxemburgo ya estamos viviendo el espíritu de la Navidad, porque este fin de semana han abierto los mercadillos navideños, concretamente el pasado viernes 21 de noviembre. Como en este país no se celebra la fiesta de los Reyes Magos, la Navidad termina el 1 de enero. Ya sabes que en España termina el día 6, aunque los estudiantes suelen tener libre incluso el 7 de enero. Y estas fechas son muy especiales para las familias que tienen a alguien enfermo, sobre todo si es un niño o un adolescente. A todas ellas, un abrazo muy fuerte desde aquí, y también una buena noticia que compartir. Porque hoy vamos a hablar de un tema muy importante: la lucha contra el cáncer y un nuevo tratamiento que está funcionando en España. Pero antes vamos a explicar algunas diferencias entre la sanidad pública y la sanidad privada en mi país. En España, la sanidad pública está financiada por los impuestos y las cotizaciones sociales. Esto significa que, si trabajas y cotizas, tienes acceso gratuito a médicos, hospitales y urgencias. Solo hay que pagar una parte de los medicamentos, lo que se llama copago. Por ejemplo, una persona con ingresos bajos puede pagar unos 8 euros por un medicamento que cuesta mucho más. Por otro lado, la sanidad privada funciona con seguros médicos. Las personas pagan una póliza mensual para tener acceso más rápido a especialistas, elegir médico o recibir servicios extra como atención dental o revisiones oftalmológicas, de la vista. Los precios varían: un joven puede pagar unos 20 o 30 euros al mes, mientras que una persona mayor puede pagar más de 100 euros mensuales. Muchas personas en España combinan ambos sistemas: usan la sanidad pública para lo esencial y contratan un seguro privado para evitar listas de espera o tener más comodidad. Con esta información como contexto, vamos a escuchar una noticia que nos habla de un avance médico realizado en un hospital público. Y es que el Hospital de La Paz, en Madrid, ha conseguido curar a varios niños con leucemia gracias a una terapia experimental. A lo largo del episodio, vamos a aprender vocabulario relacionado con este tema. Pero lo primero es escuchar la noticia, que pertenece una vez más a Radio Nacional de España. Presta mucha atención. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” La verdad es que da gusto escuchar noticias positivas relacionadas con el cáncer, porque es una enfermedad que termina con la vida de miles de personas cada año, y los avances médicos suelen tardar mucho tiempo en llegar. Pero bueno, de vez en cuando aparecen nuevos tratamientos que funcionan, como el que nos han contado en la noticia. Con respecto al vocabulario, no he encontrado mucho que explicar, pero vamos a reforzar algunos conocimientos para que estén todavía más claros. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Ejemplos: Los médicos aplicaron una terapia experimental para tratar el cáncer que no respondía a otros tratamientos. Aunque es una terapia experimental, ha mostrado resultados muy prometedores en algunos pacientes. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Ejemplos: Después de la operación, pudo hacer vida normal y volver al trabajo. Lucía ha empezado a hacer vida normal tras superar la leucemia. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Ejemplos: Su familia lo arropó durante todo el tratamiento. En el colegio, los profesores y compañeros la están arropando mucho. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Ejemplos: Tras varios meses sin síntomas, tuvo una recaída y volvió al hospital. Las recaídas son comunes en enfermedades como la leucemia. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Ejemplos: Las células cancerosas pueden pasar desapercibidas tras el primer tratamiento. Su talento no pasó desapercibido en el concurso de canto. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Ejemplos: El tratamiento fija dos moléculas para atacar el cáncer sin dejarle escondite. Han fijado la fecha de la operación para el próximo lunes. Muy bien. Como te decía, el resto del vocabulario es bastante sencillo, y supongo que lo conoces perfectamente. Así que, escuchamos la noticia por segunda vez. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Sé que lo tienes todo muy claro, pero ya sabes que me gusta ofrecerte la noticia cambiando algunas palabras para que puedas ampliar tu vocabulario. Y es lo que voy a hacer ahora mismo. La información se refiere al sistema médico público, en concreto el Hospital de La Paz en Madrid, porque ha conseguido devolverle la salud a ocho menores —niños y adolescentes— que padecían cáncer, una variante severa de leucemia, y que ya no contaban con ninguna alternativa de recuperación. Este logro ha sido posible gracias a un procedimiento innovador con células, y ahora estos jóvenes han vuelto a tener una rutina habitual. Una de ellas, Lucía, de 15 años, ha compartido su experiencia con Radio Nacional de España. Y gracias a este método terapéutico, tiene muchos proyectos para el futuro. En concreto, Lucía ha revelado tres cosas importantes: la primera, que desea estudiar Biología; la segunda, que en el colegio la están apoyando emocionalmente mucho; y la tercera, y más relevante, que está libre de la enfermedad. Dice que se encuentra fenomenal. Antes solía tener reapariciones de la enfermedad cada año, y bastante fuertes, pero esta vez no ha tenido ninguna, y está muy feliz porque parece que, por fin, está curada. Después de 15 años de batalla contra la leucemia y cuatro recaídas, Lucía ha comenzado a retomar su vida cotidiana. El tratamiento, conocido como CAR-T en combinación, se ha aplicado a diez pacientes que ya habían pasado por quimioterapia y por trasplantes para intentar detener el avance de la dolencia. Ocho de ellos ya están libres de cáncer. El gran desafío de la leucemia son las reapariciones, ya que las células malignas, tras el primer tratamiento, pueden camuflarse en ciertas moléculas para no ser detectadas y luego volver a atacar. Lo que hace este tratamiento es dirigirse simultáneamente a dos moléculas y dejar al cáncer sin posibilidad de esconderse. El resultado, como decíamos, ocho menores recuperados y una nueva ilusión para vencer definitivamente esta enfermedad. Por cierto, me gusta mucho el verbo “camuflarse”, que es como esconderse, pero utilizando alguna estrategia especial. Por ejemplo, podemos camuflarse con un disfraz para que nadie sepa quiénes somos. Venga, vamos a escuchar la noticia por última vez y te cuento más detalles sobre el impacto del cáncer en España. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Como te decía, para concluir vamos a repasar las estadísticas más recientes sobre el cáncer infantil en España. En 2024 se registraron alrededor de 1.500 casos nuevos en niños menores de 14 años. Pero lo realmente alentador es el avance en las tasas de supervivencia. Según los últimos informes, la tasa de supervivencia a cinco años tras el diagnóstico se sitúa en un impresionante 83,9 % para menores de 0 a 14 años. Esta cifra refleja una mejora constante en comparación con décadas atrás; en los años ochenta y noventa la supervivencia estaba muy por debajo, entre el 60 % y el 70 %. Estos datos ponen en evidencia que la investigación médica y los avances terapéuticos han conseguido que hoy más del 80 % de los niños con cáncer logren superarlo. Se evidencia también que cuanto más tiempo pasa tras el diagnóstico —especialmente superados los cinco años— menor es el riesgo de recaída, gracias a programas de seguimiento sólido que permiten detectar y tratar a tiempo posibles complicaciones. Este progreso va de la mano de innovaciones como la terapia CAR‑T, de la que hemos hablado hoy, y de los múltiples esfuerzos en medicina personalizada y oncología pediátrica. El mensaje es claro: aunque cada año se diagnostican nuevos casos, las posibilidades de curación siguen mejorando, ofreciendo un horizonte mucho más esperanzador para niños y adolescentes afectados. Y ahora, como siempre, repasamos las palabras y expresiones que hemos explicado hoy. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Pues esto ha sido todo por hoy. Espero que la noticia te haya alegrado tanto como a mí, porque muchas veces sólo escuchamos malas noticias en los medios de comunicación. Ojalá encuentre más informaciones de este tipo en el futuro para poder hablar de ellas aquí. Mil gracias de nuevo por tu apoyo y hasta la próxima semana. Adiós. Escucha este episodio completo y accede a todo el contenido exclusivo de Se Habla Español. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/171214

Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients.Key Topics CoveredFundamentals of CMV ManagementDistinguishing CMV reactivation from CMV diseaseTreatment thresholds and target viral loadsProphylaxis strategies in non-allograft settingsValaciclovir dosing in general hematology populationsHigh-risk patient populationsFirst-Line TherapiesValganciclovir: advantages, disadvantages, and myelosuppressionFoscarnet: indications and monitoring strategiesTreatment-resistant CMVAllogeneic Transplant PatientsHigh-risk populations and timing of reactivationMonitoring protocols post-transplantRandomized Controlled TrialsAURORA Trial: Maribavir vs. ValganciclovirDesign: RCT comparing maribavir to valganciclovir for pre-emptive CMV therapy post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/38036487/]NEJM Letermovir Prophylaxis TrialDesign: Double-blind, placebo-controlled RCT of letermovir prophylaxis post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/29211658/]Emerging Patient PopulationsCMV in lymphoma and myeloma patients receiving CAR T-cell therapy and T-cell engaging bispecific antibodiesMonitoring and prophylaxis strategies for novel immunotherapiesImpact of CMV on post-CAR T mortality-https://pubmed.ncbi.nlm.nih.gov/40203190/

In this episode... Childhood memories. Village tales. Horse and cart. Spy radios. Milkman. Coal man.Sayings from the old days. Kelly's directory and so much more...

Fast food restaurants like Wendy's are experiencing a slowdown in business The fast-food restaurant Wendy's is planning on closing hundreds of locations throughout next year because they continue to see a slowdown in spending from their customers. They said most of their low-income consumers are cutting spending and making fewer trips with smaller purchases at the restaurants. Wendy's increased prices after the pandemic at a higher rate than grocery stores and now other fast-food restaurants have begun to add value menus to keep customers coming back, but Wendy's has held firm and not created any values for their customers. Because of this they have seen their net income decline to $44.3 million from a year ago when it was $50.2 million. Over the past year the stock has declined from around $18 a share down to under $9 a share, which is a decline of 53%. With the reduction in the stock price, the dividend yield is now 6.5% and the company trades at 10 times earnings on a forward basis. This company may be worth looking into as an investment as within in the next 6 to 12 months we could see lower end consumers stabilize.   The affordability index for people buying a home is the worst in 50 years People may be excited about buying a home because mortgage rates are around the lowest they've been in over a year, but the affordability of a home is still far out of reach for many. The reason for this, and we have talked about this for the last few years, is that the increase in the price of homes has far outpaced the increase in people's income. The 50-year average for a price-to-income ratio is around four times, and it reached a low in 1999 of around 3.6 times. But with the rapid increase of homes over the last few years, the price to income ratio has climbed to slightly over five times. Also not helping are the increases in home insurance costs and property taxes. Back in the summer of 2019, when looking at households earning $75,000, nearly 50% of those people could afford to buy a home. Today, when looking at those same households earning $75,000, only 21% would be able to afford a home. Back in 2012, the home affordability index was over 200, but it has now been cut in half to just about 100 with no signs of improving any time soon. I believe it will probably take 3 to 5 years to correct itself. If you look back in history, the affordability index does not change overnight. What will happen is probably incomes will increase slightly over the next 3 to 5 years and maybe the price of homes will either stay the same or decline slightly, which would increase the affordability index. What this means for people buying a home today is you should not have any aspirations of a rapid increase in the value of your home. What caused the problem was during the pandemic mortgage rates dropped to lows not seen in 50 years and that pushed up demand and the prices for homes climbed at a rapid rate. I believe this scenario is extremely unlikely to play out again! The brokerage firm Robinhood looks more like a gambling platform than a brokerage firm Robinhood initially went public at $38 a share in 2023 and the stock then fell to under $10 a share. It has recovered nicely since then as it's now trading around $110 a share. What has caused this shift and the huge increase in the stock price? One big reason is that the company has really allowed major speculation for their investors. Starting off with crypto, they have allowed people to buy coins like BONK, Dogwifhat and Pudgy Penguins. Just when you think there's no way they could come up with anything more speculative, surprise; they have come up with an investment known as prediction markets and event trading. Somehow the regulators have let this slide or maybe since government agencies don't move that quickly, it just has not been addressed yet. It appears for investors on their app that you can predict what the outcome will be of a football game, politics, contracts over economics, even if aliens will exist on earth this year. Chief Brokerage Officer, Steve Quirk, says this is the fastest growing business we have ever had. Robinhood stock trades over 50 times projected earnings and is looking for about $4.5 billion in revenue, which is an increase of 53% over last year. The growth appears to be there for the company, but there is so much speculation and insane crazy things there is no doubt in my mind that in the future many people will lose more money than they ever thought was possible by speculating on crazy things rather than investing into good quality businesses. A fallout in those risky "investments" could hurt Robinhood's reputation, which I believe would be bad for long term growth.    Financial Planning: The Real Cost of Employer Coverage vs. Medicare When reaching age 65, sometimes there is the option to join Medicare or stay with an employer health insurance plan.  This is most common when a spouse retires after age 65 and they have the ability to join their spouse's work plan. When comparing the cost of coverage, there is a key difference in how each affects your tax bill. Premiums paid through payroll for employer-sponsored health insurance are pre-tax, meaning you avoid federal, state, and payroll taxes such as the 6.2% Social Security, 1.45% Medicare, and 1.2% CA SDI tax in California.  This is different from a 401(k) for example where contributions are only pre-tax from federal and state taxes. For someone in the 22% tax bracket, a $500 premium would be around $300 after the tax savings. Medicare premiums on the other hand are paid with after-tax dollars and are only tax-deductible for people who itemize and have total medical expenses exceeding 7.5% of AGI, which means very few retirees actually receive any tax benefit. Additionally, Medicare Part B and D premiums may be elevated due to higher levels of income because of IRMAA. Employer health insurance can vary in coverage and cost so at times Medicare may be a more comprehensive and cost-effective option, but it is necessary to compare the after-tax costs to be sure.   Companies Discussed: Cisco Systems, Inc. (CSCO), The Walt Disney Company (DIS), Spectrum Brands Holdings, Inc. (SPB), Maplebear Inc. (CART)

Prosecutors allege that during a video-conference session with her lawyers at MDC Brooklyn, Maxwell used a large cart loaded with legal documents to block the door of a dedicated conference room, effectively preventing prison staff from entering. The filing states she was permitted to bring the cart into the video‐teleconference (VTC) room for meetings, but then “used that cart to barricade the door to the room” when staff attempted to gain access.In response, Maxwell's legal team denied the barricade claim, arguing the government was “gratuitously casting” her in a negative light to justify stricter limits on her legal material access. Following the incident, prison authorities removed and banned the use of the cart during her meetings, directing that she instead carry her documents by hand and make multiple trips if needed.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Happy Thursday you pop culture junkies!   This week's pod takes a look at the hilarious social media reactions to the rainstorm in Los Angeles. Angelenos really do lose it the moment a single raindrop hits the ground, and the memes did not disappoint. We also dive into the newest gourmet food sensation in New York, Meadow Lane, opened by a social media influencer and quickly becoming the Erewhon of the East Coast.   Plus, we get into the absolute travesty of Apple's latest accessory, the iPhone Pocket, and why the internet is collectively cringing. There are also some wonderfully awkward TikTok trends making the rounds that we can't ignore. And as always, we wrap with what to watch this week — from new releases to comfort binges you'll be obsessed with.   https://popculturemondays.com/2025/11/17/its-raining/

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

Action1, Cart.com, and Tellihealth, all based in Houston, secured spots on the Deloitte Technology Fast 500 list, which ranks North America's fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies by three-year revenue growth. Action1 provides cloud-based endpoint security and patch management, Cart.com offers an e-commerce platform for online sales and logistics, and Tellihealth delivers remote patient monitoring solutions. Their inclusion highlights Houston's increasing presence in the national technology sector.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

This is a free preview of a paid episode. To hear more, visit meetthemess.substack.comMove over, Meet the Press—it's time to MEET THE MESS!This week on the podcast, Jen and Karyn are back! The House voted to release the Epstein files, but will it actually happen? Meanwhile, Trump delivers a completely bananas speech to McDonald's franchise owners and tells a female reporter, “Quiet, piggy.”Also on deck: a behavioral scientist breaks down what it means when someone does (or doesn't) return their cart. Plus, Kim Kardashian fails the bar exam, the FDA removes the black box warning from menopause hormone therapy, and a flamingo escapes a British zoo and decides to retire on a beach in the south of France. And finally, do you have a preferred font?On Meet the Mess, bestselling authors Jen Lancaster & Karyn Bosnak dive into the messiest news stories and hottest topics of the week to give a fresh and entertaining take on current events and life in general. An extended video version with the “Hot Mess of the Week” is available to paid Substack subscribers. Visit meetthemess.substack.com for more.Meet the Merch:• https://www.etsy.com/shop/MeetTheMessConnect with us on Instagram:• https://www.instagram.com/meetthemesspod• https://www.instagram.com/jennsylvania• https://www.instagram.com/karynbosnakConnect with us on TikTok:• https://www.tiktok.com/@meetthemess• https://www.tiktok.com/@karynbosnak

If you're a leader in game dev who feels stuck, there is a path forward that levels up your leadership and accelerates your team, game, and career. Sign up here to learn more: https://forms.gle/nqRTUvgFrtdYuCbr6 Are you leading a team that has plenty of people but can't seem to get moving? You care deeply about your team and your game, but projects crawl and decisions drag in the. It's almost never just a talent problem. Instead, it's three quiet leadership mistakes that choke momentum. In this episode, you'll learn what those three mistakes are, how they're showing up in your studio, and what you can do instead so you can move faster and see real progress on your game. We break down the mistakes one by one with simple shifts you can start immediately. What You'll Learn: The Velocity Trap: Why any speed you have is "pretend" if your team doesn't share a clear North Star (Vision). The Cart in the Mud: The four specific foundational elements you must have in place to earn the right to scale , and what to do when you realize you've scaled too fast. The Crunch Lie: Why overwork and extended crunch quickly make you slower than if you never crunched at all, and how to operate at a sustainable pace. A Simple Reality Check: How to rate your studio's Vision, Scale, and Workload (1-5) to identify your biggest blocker and immediately focus your leadership energy. GameDeveloper.com Article: https://www.gamedeveloper.com/production/addressing-crunch-the-games-industry-s-worst-practice-2 Connect with us:

Every successful surgery starts with a perfectly assembled case cart. But what happens when the next cart rolling into the OR is missing a critical supply or instrument? This week, we're joined by Courtney Kleeb, Senior Director of Perioperative Surgical Solutions at HealthTrust Performance Group, for a deep dive into what really drives case cart success. From preference card cleanup to fixing inefficient pick paths that send your team zigzagging, Courtney breaks down the real-world strategies that turn incomplete carts into streamlined workflows. Whether you're dealing with multiple departments all touching the same cart or just tired of chasing down missing supplies between cases, this conversation has the practical solutions you need to unite your OR, SPD, and Supply Chain around one goal—delivering excellent patient care! Season 30 of Beyond Clean releases under the 1 Episode = 1 CE delivery model. After finishing this interview, earn your 1 CE credit immediately by passing the short quiz linked here: https://www.flexiquiz.com/SC/N/episode30-07 Visit our CE Credit Hub at https://www.beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits. #BeyondClean #SterileProcessing #Podcast #Season30 #TrayCommand #CaseCarts #Accuracy #Surgery #SurgicalSupplies #Instruments

In a conversation with CancerNetwork®, Michael Barish, PhD, spoke about an investigational CAR T-cell therapy that he and colleagues are developing as a treatment for patients with glioblastoma. He and his team designed the agent to harness chlorotoxin, an amino acid peptide toxin component of scorpion venom, as a vehicle for intratumoral delivery of therapy for this patient population. Barish, a chair in the Department of Neurosciences/Developmental & Stem Cell Biology at City of Hope, discussed the background and mechanisms surrounding this novel compound, which he and colleagues evaluated as part of a phase 1 trial (NCT04214392). Early findings published in Cell Reports Medicine showed that among 4 patients with recurrent glioblastoma, 3 (75%) achieved a best response of stable disease. Additionally, the chlorotoxin-directed cellular therapy was found to be well-tolerated with no dose-limiting toxicities. Although responses were not as strong as Barish and colleagues had hoped, he described how the study nevertheless demonstrated the safety and feasibility of this CAR T-cell therapy formulation.  After establishing the safety of the novel agent in patients with recurrent glioblastoma, Barish highlighted how next steps for research included engineering different versions of the chlorotoxin and modifying the T cells that express the chimeric receptor. He stated these reconfigurations may help yield additional power and efficacy of the cellular therapy in future studies. Overall, Barish noted how the potential therapeutic application of the neurotoxin represented a “proof of principle.” “[V]enoms of many invertebrates are, in fact, very powerful biologically. In a sense, evolution has honed them to be relatively specific. Neurobiology is very much driven by the specificity of different toxins for different ion channels,” Barish stated. “This idea—that one could use biological products efficiently this way for something as heterogeneous as glioblastoma—might be an example of how it could be more efficacious for other solid tumors as well.” Reference Barish ME, Aftabizadeh M, Hibbard J, et al. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety. Cell Rep Med. 2025;6(8):102302. doi:10.1016/j.xcrm.2025.102302.

Bryan Nooner, Owner & CEO of Midwest Innovations, joins HouseSmarts Radio for Lou's Cool Products Show to share the Rhino Cart, a lightweight, but heavy-duty moving cart that can move up to 2,000lbs! Get yours at rhinocart.com.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Subscribe to DTC Newsletter - ⁠https://dtcnews.link/signup⁠Welcome to the episode: we've got Jordan Gordon back on the mic — the guy leading email, retention and CRO at Pilot House, with 25 years in ecommerce under his belt.Role‑Based Hook (for DTC growth/marketing audience):For DTC founders & growth marketers scaling from $5M–100M in revenue, this is your CRO check‑list for Q4.Here's what we dig into:Why your headline conversion rate is a shaky metric — and why “direct conversion” gives you better signal.The one page type (your top product page) you can fix in time for Black Friday to move the needle.How to push “bundling and recommendations” tools to unlock +8–30% lift in AOV with zero extra ad spend.The eight choke‑points across homepage → category → PDP → cart/checkout you must optimize right now.Real copy & button tips: How a tiny phrase (“Feel organic again”) can flip the homepage from meh to go‑time.Who this is for: DTC brand leads, ecommerce CRO/optimization folks, retention & growth marketers who already run advertising and now need to tighten the funnel.What to steal:Run quick benchmark: Are you hitting 5‑7% Add‑to‑Cart, ~2% conversion, ~1.25% direct conversion in Shopify?Pick your top 3‑5 PDPs and make them ultra‑fast (under 3s load) using a tool/tech stack like Niche.Install a bundling/recommendation engine (like Rebuy) across the site and measure +8% lift in AOV by pushing “people like you bought this + add it” flows.Timestamps00:00 Highest Leverage CRO Insights for Q402:10 Benchmarking Add-to-Cart and Conversion Rates04:45 Why Direct Conversion Is a Better Signal07:00 Speeding Up PDPs with Niche for Instant Wins10:05 Boosting AOV with Rebuy Bundling13:00 The 8 Critical Website Choke Points15:45 Optimizing Copy Around Key Conversion Areas18:20 Homepage Strategy for High-Volume Traffic21:40 What Big Brands Get Right on Their Homepages24:30 Final Q4 CRO Checklist and Fast WinsHashtags#dtcpodcast #q4ecommerce #cro #conversionrateoptimization #ecommercetips #shopifygrowth #blackfridayprep #aov #d2cbrands #onlinescaling Subscribe to DTC Newsletter - https://dtcnews.link/signupAdvertise on DTC - https://dtcnews.link/advertiseWork with Pilothouse - https://www.pilothouse.co/?utm_source=AKNF559Follow us on Instagram & Twitter - @dtcnewsletterWatch this interview on YouTube - https://dtcnews.link/video

Welcome to another electrifying episode of the Lighting Controls Podcast! This time, we're joined by industry veteran Dave Werry, who brings over a decade of hands-on experience in lighting systems, engineering, and field service. 

Send us a textUnderstanding your Amazon customer journey is crucial for sales growth. Learn how to analyze awareness, consideration, and purchase stages to optimize your strategies with the help of My Amazon Guy's expert insights. Discover the steps you can take to fine-tune your advertising and customer targeting for maximum success.Get your hands on the Ultimate Q4 Playbook for Amazon sellers and crush this holiday season! https://bit.ly/46Wqkm3Book a strategy call to dive deeper into your customer journey analytics and unlock real growth for your brand: https://bit.ly/4jMZtxu#AmazonSales #EcommerceGrowth #CustomerJourney #AmazonAdvertising #brandgrowth Watch these videos on YouTube:Use Brand Analytics to Increase Sales https://www.youtube.com/watch?v=HnUKZXZ9uEk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=4Simplify Amazon Listing Compliance https://www.youtube.com/watch?v=ArGPygUCFpk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=11-----------------------------------------------Plan your best sales season yet with our 2025 Ecommerce Holiday Playbook: https://bit.ly/4hbygovStop wasting ad spend,download our PPC guide and run campaigns that actually convert: https://bit.ly/4lF0OYXFix what's burying your listings, download the SEO toolkit sellers rely on for rankings: https://bit.ly/3JyMDGoDon't wait for chaos, grab the Amazon Crisis Kit before your traffic or rankings take a hit: https://bit.ly/4maWHn0Timestamps00:00 - Amazon Data & Customer Journey01:10 - Understanding the Amazon Customer Journey Funnel02:20 - Analyzing the Awareness Stage: Key Metrics03:40 - Identifying High Potential Customers in Consideration05:00 - The Importance of Add-to-Cart and Wishlist Data06:15 - How to Optimize Your Amazon Sales Funnel for Better Conversion07:30 - Comparing January vs. March: Key Data Shifts08:45 - Improving New-to-Brand Purchases with Targeted Strategies10:00 - Retargeting Strategies for Repeat Customers on Amazon11:15 - How to Leverage Customer Journey Data to Grow Your Brand----------------------------------------------Follow us:LinkedIn: https://www.linkedin.com/company/28605816/Instagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Twitter: https://twitter.com/myamazonguySubscribe to the My Amazon Guy podcast: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

Do the 2001 Patriots compare to the 2025 Patriots in significant ways? // Former Patriots' QB Brian Hoyer joins, says Pats are the real deal // Comparing Maye to Brady //

Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, former director of the Cell Technology Group at Oxford Biomedica, and Kyriacos Mitrophanous, PhD, Chief Innovation Officer at Oxford Biomedica, to discuss an article recently published in Molecular Therapy by Nimmo and colleagues titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.” Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. full 2118 Mon, 10 Nov 2025 23:00:00 +0000 BYpLLrNBGkJzXjHRjldrmzcuuqbqEygf news The Dana & Parks Podcast news HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://player.am

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Memory chip stocks like SanDisk (SNDK), Seagate (STX) and Western Digital (WDC) gathered more bullish traction from firms like Loop Capital and Barclays. Diane King Hall explains where the Street is seeing more upside for these companies and the role A.I. plays in their theses. Healthcare stocks dipped after President Trump made comments against health insurers on Truth Social. Diane later turns to Instacart's parent company, Maplebear (CART), which delivered a double-win in earnings through a beat and share buyback announcement.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Revolutionizing Retail: Drew Ann Long's Caroline's Cart Journey In this episode of 'Why Not Me', hosted by Tony Mantor from Nashville, Tennessee Drew Ann Long shares her inspiring story of creating Caroline's Cart—a revolutionary shopping cart designed for individuals with special needs. Drew Ann, motivated by her daughter Caroline's severe disabilities, overcame numerous challenges, financial hurdles, and industry skepticism to bring her vision to life. Despite initial rejections from manufacturers, Drew's relentless pursuit led to global recognition and adoption of Caroline's Cart, transforming accessibility in retail. She also discusses the formation of Caroline's Cause, a nonprofit providing scholarships to families with special needs children. Drew's journey highlights the impact of empathy-driven innovation and the importance of taking bold risks to make a difference. Meet Drew Ann Long: Founder of Caroline's Cart The Birth of Caroline's Cart Challenges and Breakthroughs The First Prototype and Social Media Explosion Manufacturing Struggles and Success Nationwide and International Expansion Caroline's Cause: Giving Back Future Plans and Continued Growth Closing Thoughts and Contact Information Music written By T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This month, the gals are joined by Trevin from Live, Laugh, Larceny Podcast to discuss a wiener catastrophe, poop spray damage, Sierra's stains, litter at the country club, a food critic for the people, and the most accident-prone pastor you've ever heard of. Tune in for October's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.